GSGTF (Gensight Biologics) Effective Interest Rate on Debt %: 23.27% (As of Dec. 2025)


What is Gensight Biologics Effective Interest Rate on Debt %?

Gensight Biologics GSGTF Effective Interest Rate on Debt % is 23.27% as of Dec. 2025. The stock has 8 warning signs investors should review.

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Gensight Biologics's annualized positive value of Interest Expense for the quarter that ended in Dec. 2025 was $3.67 Mil. Gensight Biologics's average total debt for the quarter that ended in Dec. 2025 was $15.79 Mil. Therefore, Gensight Biologics's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2025 was 23.27%.

Gensight Biologics  (OTCPK:GSGTF) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Gensight Biologics Effective Interest Rate on Debt % Related Terms

Gensight Biologics Effective Interest Rate on Debt % Historical Data

* Premium members only.

The historical data trend for Gensight Biologics's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gensight Biologics Effective Interest Rate on Debt % Chart

Gensight Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.40 20.34 20.52 9.24 22.44

Gensight Biologics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.06 2.14 16.80 19.26 23.27

GSGTF vs VRTX, REGN, ALNY: Effective Interest Rate on Debt % Comparison

For the Biotechnology subindustry, Gensight Biologics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gensight Biologics Effective Interest Rate on Debt % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gensight Biologics's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Gensight Biologics's Effective Interest Rate on Debt % falls into.


Gensight Biologics Effective Interest Rate on Debt % Calculation

Gensight Biologics's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2025 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2024 )+Total Debt  (A: Dec. 2025 ))/ count )
=-1  *  -3.383/( (15.092+15.062)/ 2 )
=-1  *  -3.383/15.077
=22.44 %

where

Total Debt  (A: Dec. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.538 + 14.554
=15.092

Total Debt  (A: Dec. 2025 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=10.797 + 4.265
=15.062

Gensight Biologics's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2025 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Jun. 2025 )+Total Debt  (Q: Dec. 2025 ))/ count )
=-1  *  -3.674/( (16.512+15.062)/ 2 )
=-1  *  -3.674/15.787
=23.27 %

where

Total Debt  (Q: Jun. 2025 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.414 + 16.098
=16.512

Total Debt  (Q: Dec. 2025 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=10.797 + 4.265
=15.062

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is two times the semi-annual (Dec. 2025) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

What does a Effective Interest Rate on Debt % of 23.27% mean?
Gensight Biologics (GSGTF) has a Effective Interest Rate on Debt % of 23.27% as of Dec. 2025. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Gensight Biologics and its competitors.
Is Gensight Biologics' Effective Interest Rate on Debt % too high?
Gensight Biologics' current Effective Interest Rate on Debt % is 23.27%.
How does Gensight Biologics' Effective Interest Rate on Debt % compare to VRTX and REGN?
Gensight Biologics' Effective Interest Rate on Debt % of 23.27% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Effective Interest Rate on Debt % for a Biotechnology company?
A good Effective Interest Rate on Debt % depends on the Biotechnology industry context. However, Effective Interest Rate on Debt % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Effective Interest Rate on Debt % mean?
A high Effective Interest Rate on Debt % can signal that a stock is expensive relative to its fundamentals. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Gensight Biologics and its competitors. Gensight Biologics's current Effective Interest Rate on Debt % is 23.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gensight Biologics stock overvalued right now?
Based on GuruFocus' analysis, Gensight Biologics (GSGTF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.04, compared to a current price of $0.09 — trading 125% above its estimated fair value. The current Effective Interest Rate on Debt % is 23.27%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Effective Interest Rate on Debt % calculated?
Effective Interest Rate on Debt % is calculated from a company's financial statements. For Gensight Biologics (GSGTF), the current Effective Interest Rate on Debt % is 23.27% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gensight Biologics Business Description

Address 74, rue du Faubourg Saint-Antoine, Paris, FRA, 75012
Gensight Biologics SA is a clinical-stage biopharma company focused on developing and commercializing gene therapies for retinal neurodegenerative diseases and central nervous system disorders. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.